Moderna Stock

Moderna Forward P/E

The Forward P/E Ratio of Moderna (MRNA) as of Aug 4, 2026 is -5.85. In the previous year, Forward P/E Ratio was -4.63 — a change of 26.19% (lower).

Forward P/E

-5.85

YoY

26.19%

Last updated:

Forward P/E Ratio of Moderna is 2026 -5.85 . Forward P/E Ratio of Moderna was 2025 -4.63 . It decreases by 26.19% lower compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

Forward P/E Ratio of Moderna is -5.85 in 2026.

Forward P/E Ratio of Moderna changed from -4.63 to -5.85, representing a 26.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Moderna since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Moderna with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Moderna

All Key Metrics — Moderna